Virtual Library

Start Your Search

Massey Nematollahi



Author of

  • +

    MTE12 - IO in the Real World - High Risk Populations And Patient Support (Ticketed Session) (ID 822)

    • Event: WCLC 2018
    • Type: Meet the Expert Session
    • Track: Immunooncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/25/2018, 07:00 - 08:00, Room 206 AC
    • +

      MTE12.02 - How can we Minimize Toxicity for our High Risk Patients? (Now Available) (ID 11567)

      07:40 - 08:00  |  Presenting Author(s): Massey Nematollahi

      • Abstract
      • Presentation
      • Slides

      Abstract

      This session will focus on strategies and innovative approaches to minimize cancer immuno-therapy toxicities.

      Immune checkpoint inhibitors (ICI) are a new class of anti-neoplastic agents termed immuno-therapy and are now standard of practice for lung cancer population including elderly with comorbidities. These agents have significantly impacted patient outcomes by offering durable responses. However, the effective and safe delivery of these agents require expertise in understanding the unique characteristics of the ICI (Immune Checkpoint Inhibitors) that differ from cytotoxic chemotherapy. Certain immunotherapy protocols may have up to 50% rate of developing severe irAEs. The number of indications of ICI treatment is rapidly evolving and broadening thus being proactive in developing a specialized clinic for these patients would not only centralize care and optimize efficacy but minimize toxicities in high risk population.

      Currently there is a large unmet need for an education class for patients prior to starting immunotherapy. Many centers have “chemotherapy teaching class” which are attended by all patients prior to starting chemotherapy, however the information regarding toxicities does not apply to ICI and could lead to under reporting of IrAEs particularly in high risk population with comorbidities and elderly.

      At William Osler Health Center, under supervision of Dr. Parneet Cheema an immune-oncology clinic has been established.

      Objective:

      The objective of this initiative is to generate a standardized, reproducible, and safe implementation immunotherapy program that could be easily recreated at any community cancer center.

      This presentation will discuss the clinic design, immunotherapy teaching class, logistics and standardized ICI delivery, care monitoring, and follow-up.

      e353dbe42c8654f33588d4da0b517469

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    WS05 - ITONF Workshop: Excellence in Thoracic Oncology Care (ID 889)

    • Event: WCLC 2018
    • Type: Workshop
    • Track: Nursing and Allied Professionals
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/23/2018, 12:00 - 18:00, Room 206 BD
    • +

      WS05.02 - Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada (Now Available) (ID 14542)

      12:30 - 13:00  |  Presenting Author(s): Massey Nematollahi

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.